All Q1 FY26 results →

S

Sanofi

Q1 FY26Pharmaceuticals

Sanofi Q1 FY26 Results — Earnings Call Analysis

Q1 FY26 earnings call: what management said on revenue, margins and capex.

Price₹44

Market cap₹1.1L Cr

P/E19.2

Updated29 May 2026

Read4 min read

What the Q1 FY26 call signalled

1 of 4 strong

RevenueSlow growth

MarginMargins steady

CapexCapex planned

FundraiseNo fundraise planned

The short version

- For 2026, Sanofi expects sales to grow by a high single-digit percentage and business EPS to grow slightly faster than sales, continuing profitable growth over at least 5 years. - In 2026, Sanofi expects sales to grow by a high single-digit percentage.

From Sanofi's Q1 FY26 earnings-call transcript · updated 29 May 2026.

Revenue & Sales Performance

Slow growth

For 2026, Sanofi expects sales to grow by a high single-digit percentage and business EPS to grow slightly faster than sales, continuing profitable growth over at least 5 years. (Page 16)
Long-term ambition includes pursuing earnings growth into the next decade based on pipeline and external growth opportunities. (Page 16)
Vaccine sales are expected to slightly decline in 2026 amid ongoing portfolio optimization. (Page 3)
Strong growth drivers include expansion of Dupixent with multiple indications and new medicine launches like Qfitlia, Wayrilz, and Nuvaxovid. (Pages 2, 16)

2 more points from Sanofi's call on revenue

Create a free account to keep reading this call

Profitability & Margins

In 2026, Sanofi expects sales to grow by a high single-digit percentage.
Business EPS (Earnings Per Share) is anticipated to grow slightly faster than sales in 2026.
Profitable growth is projected to continue for at least 5 years from 2025 onwards.
The company aims to pursue earnings growth into the next decade, supported by its pipeline and external growth opportunities.
For 2026, the outlook includes:
Sales growth close to 2025’s performance (9.9% in 2025).
Operating income to include around EUR 500 million of capital gains from disposals.
Stable effective tax rate.

2 more points from Sanofi's call on margins

Create a free account to keep reading this call

See what Sanofi said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

Capex planned

In 2025, Sanofi significantly increased organic growth investments in R&D, commercial capabilities, CapEx, and digital transformation to fuel current and future growth.
They deployed proceeds from the Opella divestment into strategic acquisitions such as Blueprint, Vicebio, Dren Bio DR-0201, and Vigil to accelerate transformation.
Moderate increase expected in underlying R&D expenses for 2026, alongside added placeholder for potential future acquisitions, particularly Phase I and II assets.
Sales and marketing expenses will rise in 2026 to support growth and launches.
Stable G&A expenses targeted in 2026.
A EUR 1 billion share buyback program is planned for 2026, continuing capital allocation policy focused on sustainable value creation and shareholder returns while investing in long-term growth opportunities.

2 more points from Sanofi's call on capex

Create a free account to keep reading this call

Fundraising & Capital Structure

Sanofi ended 2025 with a strong capital structure and low net debt of EUR 11 billion.
Maintained a conservative net debt-to-EBITDA ratio of 0.8x, supporting financial flexibility.
The company has significant financial flexibility for future external growth opportunities while maintaining its AA rating.
Instead, focus on disciplined capital allocation and use of existing financial resources.
Planned to execute a EUR 1 billion share buyback program in 2026, continuing shareholder returns.

2 more points from Sanofi's call on fundraising

Create a free account to keep reading this call

See what Sanofi said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

Relevant financial and business outlook details related to growth and pipelines include: - In 2025, Sanofi achieved strong profitable growth, with sales increasing by 9.9% and business EPS growing by 15%. - For 2026, sales are expected to grow by a high single-digit percentage, with business EPS growing slightly faster than sales. - Continued profitable growth is anticipated over at least the next 5 years. - The company is targeting strong free cash flow generation (at least 20% of net sales medium-term) with disciplined inventory management. - Sales dynamics in 2026 include portfolio optimization with divestments reducing sales by about EUR 200 million.

2 more points from Sanofi's call on order book

Create a free account to keep reading this call

Others in Pharmaceuticals this season

Haleon plc (Q1 FY26)
Haleon plc Q1 FY26 quarterly results analysis. Organic sales growth guidance for 2026 is 3% to 5%, signaling some sequential acceleration from 3% in 2025. Marke
Takeda Pharmaceutical Company Limited (Q1 FY26)
Takeda Pharmaceutical Company Limited Q1 FY26 quarterly results analysis. Growth in plasma-derived therapies (PDT) expected to be mid-single-digit growth for th
Novo Nordisk A/S (Q1 FY26)
Novo Nordisk A/S Q1 FY26 quarterly results analysis. 2026 sales growth is expected to be negative, with adjusted sales growth projected at -5% to -13% at consta
Novartis AG (Q1 FY26)
Novartis AG Q1 FY26 quarterly results analysis. Novartis expects low single-digit sales growth in 2026 despite significant patent expiries and generic competiti

Compare:vs AstraZeneca PLC vs Johnson & Johnson vs Novartis AG

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Sanofi and 15K+ more earnings calls,
for less than your morning chai

a day

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Sanofi Q1 FY26 results?

- For 2026, Sanofi expects sales to grow by a high single-digit percentage and business EPS to grow slightly faster than sales, continuing profitable growth over at least 5 years. - In 2026, Sanofi expects sales to grow by a high single-digit percentage.

What is Sanofi share price analysis?

Sanofi currently shows a neutral. The stock trades at a P/E of 19.2 with a market cap of $108,017. Investors should review the full earnings analysis for detailed insights.

Is Sanofi planning capital expenditure?

- In 2025, Sanofi significantly increased organic growth investments in R&D, commercial capabilities, CapEx, and digital transformation to fuel current and future growth.

Keep Sanofi on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.